NSUN5 as a Prognostic Biomarker Correlates with Malignant Phenotype and Therapeutic Target in Glioma
Open Access
- 19 January 2026
- journal article
- Published by Wiley in Brain and Behavior
- Vol. 16 (1) , e71211
Abstract
Background: NSUN5 is a conserved RNA methyltransferase whose oncogenic role has been demonstrated in various cancers. However, its function and prognostic value in gliomas remain unclear. Methods: In this study, we systematically analyzed the expression and functional associations of NSUN5 in glioma using data from The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases. A total of 117 machine learning algorithm combinations were employed to construct and validate a prognostic model for glioma patients. In addition, in vitro experiments were performed to further validate the expression and biological functions of NSUN5. Results: NSUN5 expression is significantly upregulated in glioma and is positively associated with tumor malignancy and poor prognosis. Immune infiltration analysis revealed a marked increase in M2 macrophages in the NSUN5 high‐expression group, and NSUN5 levels were positively correlated with the expression of multiple inhibitory immune checkpoints. In addition, drug sensitivity analysis and molecular docking suggested that NSUN5 may influence the response to Olaparib. Finally, based on NSUN5‐associated genes, we constructed 117 machine learning models and identified the optimal prognostic model, STRICOM, which demonstrated robust predictive performance for patient survival. Conclusion: High NSUN5 expression is closely associated with poor prognosis in glioma patients, highlighting its potential as a prognostic biomarker and therapeutic target.Keywords
Funding Information
- National Natural Science Foundation of China
This publication has 47 references indexed in Scilit:
- Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational programActa Neuropathologica, 2019
- Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncologyBioinformatics, 2019
- Glioma Subclassifications and Their Clinical SignificanceNeurotherapeutics, 2017
- Management of Gliomas: Overview of the Latest Technological Advancements and Related Behavioral DrawbacksBehavioural Neurology, 2015
- Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2Hepatology, 2014
- Widespread occurrence of 5-methylcytosine in human coding and non-coding RNANucleic Acids Research, 2012
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapyJournal of Neuro-Oncology, 2008
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005